Systemic delivery of small interfering RNA targeting the interleukin-2/15 receptor β chain prevents disease progression in experimental arthritis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhang, Tiantian ^a   Bai, Xuehua ^a   Mao, Xiaohua ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR BETA CHAIN; INTERLEUKIN 2 RECEPTOR; NANOPARTICLE; POLYETHYLENEIMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG TARGETING; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC THERAPY; T LYMPHOCYTE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE PROGRESSION; DRUG CARRIERS; GENE SILENCING; HINDLIMB; INTERLEUKIN-15; INTERLEUKIN-1BETA; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MACROPHAGES; MALE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; POLYETHYLENEIMINE; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892424496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078619     Document Type: Article

References (39)

1. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. Jô Clin Invest 118: 3537-3545.
2. McInnes IB, O'Dell JR (2010) State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 69: 1898-1906.
3. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, et al. (1996) The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2: 175-182.
4. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY (1997) Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 3: 189-195.
5. Asquith DL, McInnes IB (2007) Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 19: 246-251.
6. McInnes IB, Gracie JA (2004) Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4: 392-397.
7. Waldmann TA, Tagaya Y (1999) The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17: 19-49.
8. Ernestam S, af Klint E, Catrina AI, Sundberq E, Enqstrom M, et al. (2006) Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor. Arthritis Res Ther 8: R18.
9. Andersson AK, Feldmann M, Brennan FM (2008) Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scandô Jô Immunol 68: 103-111.
10. González-Álvaro I, Ortiz AM, Alvaro-Gracia JM, Castañeda S, Díaz-Sánchez B, et al. (2011) Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One 6(12): e29492.
11. Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, et al. (2012) Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis 71: 1651-1657.
12. Schett G, Gravallese E (2012). Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8: 656-664.
13. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY (1998) Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. Jô Immunol 160: 5654-5660.
14. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, et al. (2004) Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. Jô Immunol 173: 5818-5826.
15. Wang D, Deng X, Leng X, Mao X (2010) Interleukin-15 receptor-directed immunotoxins atteunuate disease severity in rat adjuvant arthritis. Mol Immunol 47:1535-1543.
16. Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34: 322-333.
17. Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97: 14-32.
18. Schindler CW (2002) Series introduction. JAK-STAT signaling in human disease. Jô Clin Invest 109: 1133-1137.
19. Kurreeman FA, Daha NA, Chang M, Catanese JJ, Begovich AB, et al. (2009) Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann Rheum Dis 68: 1789-1790.
20. Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M (2006) Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. Ann Rheum Dis 65: 26-29.
21. Gao J, Liu W, Xia Y, Li W, Sun J, et al. (2011) The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32: 3459-3470.
22. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
23. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. Jô Clin Invest 117: 3623-3632.
24. Guo S, Huang Y, Jiang Q, Sun Y, Deng L, et al. (2010) Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano, 4: 5505-5511.
25. Bonnet ME, Erbacher P, Bolcato-Bellemin AL (2008) Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 25: 2972-2982.
26. Khoury M, Louis-Plence P, Escriou V, Noel D, Largeau C, et al. (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54: 1867-1877.
27. Khoury M, Escriou V, Courties G, Galy A, Yao R, et al. (2008) Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 58: 2356-2367.
28. Ye C, Bhan A, Deshpande V, Shankar P, Manjunath N (2013) Silencing TNF-α in macrophages and dendritic cells for arthritis treatment. Scandô Jô Rheumatol 42: 266-269.
29. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, et al. (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. Jô Immunol 162: 2754-2760.
30. Bachmann MF, Oxenius A (2007) Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep 8: 1142-1148.
31. Mitragotri S, Yoo JW. (2011) Designing micro- and nano-particles for treating rheumatoid arthritis. Arch Pharm Res 34: 1887-1897.
32. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, et al. (2007) Renal clearance of quantum dots. Nat Biotechnol 25: 1165-1170.
33. Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, et al. (2009) Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett 9: 2354-2359.
34. Zuckerman JE, Choi CH, Han H, Davis ME (2012) Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sciô Uô Sô A 109: 3137-3142.
35. Naeye B, Deschout H, Caveliers V, Descamps B, Braeckmans K, et al. (2013) In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34: 2350-2358.
36. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, et al. (2009) Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 17: 162-168.
37. Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 45: 101-106.
38. Fröhlich E (2012) The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Intô Jô Nanomedicine 7: 5577-5591.
39. Dépis F, Hatterer E, Lamacchia C, Waldburger JM, Gabay C, et al. (2012) Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments. Arthritis Rheum 64: 3189-3198.